medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2009, Número 3

<< Anterior Siguiente >>

Rev Invest Clin 2009; 61 (3)


Vinculación de Nef con los determinantes inmunológicos y virológicos del SIDA

Gomez-Icazbalceta G, Larralde C

Idioma: Español
Referencias bibliográficas: 63
Paginas: 243-251
Archivo PDF: 120.99 Kb.


RESUMEN

Nef es una proteína accesoria del VIH-1 que promueve la replicación viral, la depleción de linfocitos T CD4+ y la progresión al SIDA. La participación de Nef en la modificación de los diferentes componentes celulares y subcelulares ha sido estudiada en detalle. El hallazgo de que pacientes infectados por más de 15 años con variantes del VIH -1 que expresaban una variante defectuosa del gen nef no habían progresado al SIDA en más de quince años de infección, sugirió que Nef jugaba un papel determinante en el desencadenamiento del SIDA a través de la regulación de los diferentes componentes virológicos e inmunológicos. Además, la sola expresión de Nef es capaz de inducir un cuadro similar al SIDA en ratones transgénicos y de alterar la cinética de replicación del virus en monos infectados. En esta revisión se analiza la relación entre la expresión de Nef y las consecuencias finales de la infección por el VIH-1, tomando en cuenta los parámetros clínicos más relevantes: carga viral, cuenta de linfocitos T CD4+ y progresión al SIDA. Bajo ese enfoque, se enfatiza el papel inmunomodulador de Nef y además se sugiere que Nef posee un potencial independiente de daño al sistema inmune.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Larralde C, Huerta L. Network between main protagonists and events leading to AIDS. Arch Med Res 1996, 27: 107-13.

  2. Goedert JJ, Gallo RC. Epidemiological evidence that HTLV-III is the AIDS agent. Eur J Epidemiol 1985, 1: 155-9.

  3. Battegay M, Nüesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006, 6: 280-7.

  4. Cohen J. AIDS. The unanswered questions. Science 1993; 260: 1253-93.

  5. Learmont J, Tindall B, Evans L, Cunningham A, et al. Longterm symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992; 340: 863-7.

  6. Gorry PR, Churchill M, Learmont J, Cherry C, et al. Replication- dependent pathogenicity of attenuated nef-deleted HIV-1 in vivo. Acquir Immune Defic Syndr 2007; 46: 390-4.

  7. Greenway AL, Holloway G, McPhee DA, Ellis P, et al. HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication. J Biosci 2003; 28: 323-35.

  8. Fenard D, Yonemoto W, de Noronha C, Cavrois M, et al. Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. J Immunol 2005; 175: 6050-7.

  9. Liu X, Schrager JA, Lange GD, Marsh JW. HIV Nef-mediated cellular phenotypes are differentially expressed as a function of intracellular Nef concentrations. J Biol Chem 2001; 276: 32763-70.

  10. Li PL, Wang T, Buckley KA, Chenine AL, et al. Phosphorylation of HIV Nef by cAMP-dependent protein kinase. Virology 2005; 331: 367-74.

  11. Fackler OT, Moris A, Tibroni N, Giese SI, et al. Functional characterization of HIV-1 Nef mutants in the context of viral infection. Virology 2006; 351: 322-39.

  12. Collette Y, Chang HL, Cerdan C, Chambost H, et al. Specific Th1 cytokine down-regulation associated with primary clinically derived human immunodeficiency virus type 1 Nef geneinduced expression. J Immunol 1996; 156: 360-70.

  13. Choe EY, Schoenberger ES, Groopman JE, Park IW. HIV Nef inhibits T cell migration. J Biol Chem 2002; 277: 46079-84.

  14. Trkola A. HIV-host interactions: vital to the virus and key to its inhibition. Curr Opin Microbiol 2004; 7: 555-9.

  15. Wu Y, Marsh JW. Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J Virol 2003, 77: 10376-82.

  16. Mullins JI, Hoover EA, Quackenbush SL, Donahue PR. Disease progression and viral genome variants in experimental feline leukemia virus-induced immunodeficiency syndrome. J Acquir Immune Defic Syndr 1991; 4: 547-57.

  17. Wu Y, Marsh JW. Gene transcription in HIV infection. Microbes Infect 2003; 5: 1023-7.

  18. Gillim-Ross L, Cara A, Klotman ME. Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. J Gen Virol 2005; 86: 765-71.

  19. Oswald-Richter K, Grill SM, Leelawong M, Unutmaz D. HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. Eur J Immunol 2004; 34: 1705-14.

  20. Carl S, Greenough TC, Krumbiegel M, Greenberg M, et al. Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol 2001; 75: 3657-65.

  21. Collins KL, Chen BK, Kalams SA, Walker BD, et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998; 391: 397-401.

  22. Benson RE, Sanfridson A, Ottinger JS, Doyle C, et al. Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. J Exp Med 1993; 177: 1561-6.

  23. Tanaka M, Ueno T, Nakahara T, Sasaki K, et al. Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1. Virology 2003; 311: 316-25.

  24. Levesque K, Finzi A, Binette J, Cohen EA. Role of CD4 receptor down-regulation during HIV-1 infection. Curr HIV Res 2004, 2: 51-9.

  25. Connor RI, Mohri H, Cao Y, Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 1993; 67: 1772-7.

  26. Quiñones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, et al. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000; 74: 9222-33.

  27. Fujii Y, Otake K, Tashiro M, Adachi A. Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett 1996; 393: 93-6.

  28. James CO, Huang MB, Khan M, Garcia-Barrio M, et al. Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 2004; 78: 3099-109.

  29. Quaranta MG, Mattioli B, Spadaro F, Straface E, et al. HIV-1 Nef triggers Vav-mediated signaling pathway leading to functional and morphological differentiation of dendritic cells. FASEB J 2003; 17: 2025-36.

  30. Jason J, Inge KL. Modulation of CD8 and CD3 by HIV or HIV antigens. Scand J Immunol 2001; 53: 259-67.

  31. Giordani L, Giacomini E, Quaranta MG, Viora M. HIV-1 Nef protein inhibits the in vitro induction of a specific antibody response to Candida albicans by an early up-regulation of IL- 15 production. Clin Exp Immunol 2000; 122: 358-63.

  32. Koedel U, Kohleisen B, Sporer B, Lahrtz F, et al. HIV type 1 Nef protein is a viral factor for leukocyte recruitment into the central nervous system. J Immunol 1999; 163: 1237-45.

  33. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998; 95: 163-75.

  34. Schmitz JE, Johnson RP, McClure HM, Manson KH, et al. Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol 2005; 79: 8131-41.

  35. Chakrabarti LA, Metzner KJ, Ivanovic T, Cheng H, et al. A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus Ivmac239Deltanef increases viral replication. J Virol 2003; 77: 1245-56.

  36. Khan IH, Sawai ET, Antonio E, Weber CJ, et al. Role of the SH3-ligand domain of simian immunodeficiency virus Nef in interaction with Nef-associated kinase and simian AIDS in rhesus macaques. J Virol 1998; 72: 5820-30.

  37. Carl S, Daniels R, Iafrate AJ, Easterbrook P, et al. Partial “repair” of defective NEF genes in a long-term nonprogressor with human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181: 132-40.

  38. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Ann Rev Microbiol 1996; 50: 825-54.

  39. Calenda V, Graber P, Delamarter JF, Chermann JC. Involvement of HIV nef protein in abnormal hematopoiesis in AIDS: in vitro study on bone marrow progenitor cells. Eur J Haematol 1994, 52: 103-7.

  40. Douche-Aourik F, Berlier W, Féasson L, Bourlet T, et al. Detection of enterovirus in human skeletal muscle from patients with chronic inflammatory muscle disease or fibromyalgia and healthy subjects. Med Virol 2003; 71: 540-7.

  41. Tamiya S, Matsuoka M, Etoh K, Watanabe T, et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1996; 88: 3065-73.

  42. Tzavaras T, Stewart M, McDougall A, Fulton R, et al. Molecular cloning and characterization of a defective recombinant feline leukaemia virus associated with myeloid leukaemia. J Gen Virol 1990; 71: 343-54.

  43. Aziz DC, Hanna Z, Jolicoeur P. Severe immunodeficiency disease induced by a defective murine leukaemia virus. Nature 1989; 338: 505-8.

  44. Salvi R, Garbuglia AR, Di Caro A, Pulciani S, et al. Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J Virol 1998; 72: 3646-57.

  45. Casartelli N, Di Matteo G, Argentini C, Cancrini C, et al. Structural defects and variations in the HIV-1 nef gene from rapid, slow and non-progressor children. AIDS 2003; 17: 1291-301.

  46. Yamada T, Iwamoto A. Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. Arch Virol 2000; 145: 1021-7.

  47. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24: 657-79.

  48. Namazi MR. Paradoxical exacerbation of psoriasis in AIDS: proposed explanations including the potential roles of substance P and gram-negative bacteria. Autoimmunity 2004; 37: 67-71.

  49. Birch MR, Learmont JC, Dyer WB, Deacon NJ, et al. An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J Clin Virol 2001; 22: 263-70.

  50. Smith SM. The pathogenesis of HIV infection: stupids may not be so dumb after all. Retrovirology 2006; 3: 60.

  51. Naylor K, Li G, Vallejo AN, Lee WW, Koetz K, et al. The influence of age on T cell generation and TCR diversity. J Immunol 2005; 174: 7446-52.

  52. Ling B, Apetrei C, Pandrea I, Veazey RS, et al. Classic AIDS in a sooty mangabey after an 18-year natural infection. J Virol 2004; 78: 8902-8.

  53. Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, et al. Increased frequency of CCR-5 delta 32 heterozygotes among longterm non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS 1997; 11: 1833-8.

  54. Agrawal L, Jin Q, Altenburg J, Meyer L, et al. CCR5Delta32 protein expression and stability are critical for resistance to human immunodeficiency virus type 1 in vivo. J Virol 2007; 81: 8041-9.

  55. Jansen CA, Piriou E, Bronke C, Vingerhoed J, et al. Characterization of virus-specific CD8(+) effector T cells in the course of HIV-1 infection: longitudinal analyses in slow and rapid progressors. Clin Immunol 2004; 113: 299-309.

  56. Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, et al. Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007; 104: 6776-81.

  57. Dyer WB, Ogg GS, Demoitie MA, Jin X, et al. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J Virol 1999; 73: 436-43.

  58. Keoshkerian E, Ashton LJ, Smith DG, Ziegler JB, et al. Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression. J Med Virol 2003; 71: 483-91.

  59. Jin X, Bauer DE, Tuttleton SE, Lewin S, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus- infected macaques. J Exp Med 1999; 189: 991-8.

  60. Odermatt B, Eppler M, Leist TP, Hengartner H, et al. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. Proc Natl Acad Sci U S A 1991; 88: 8252-6.

  61. Gómez-Icazbalceta G, Huerta L, Soto-Ramirez LE, Larralde C. Extracellular HIV-1 Nef protein modulates lytic activity and proliferation of human CD8+ T lymphocytes. Cell Immunol 2007; 250: 85-90.

  62. James CO, Huang MB, Khan M, Garcia-Barrio M, et al. Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 2004; 78: 3099-109.

  63. Zlotnik A. Chemokines and cancer. Int J Cancer 2006; 119: 2026-9.




2020     |     www.medigraphic.com